Squarepoint’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.32M | Sell |
25,524
-66,923
| -72% | -$3.41M | ﹤0.01% | 2534 |
|
|
2025
Q4 | $4.59M | Buy |
92,447
+25,158
| +37% | +$1.22M | ﹤0.01% | 1516 |
|
|
2025
Q3 | $3.22M | Sell |
67,289
-52,689
| -44% | -$2.12M | ﹤0.01% | 1737 |
|
|
2025
Q2 | $3.78M | Buy |
119,978
+46,711
| +64% | +$1.5M | ﹤0.01% | 1653 |
|
|
2025
Q1 | $2.4M | Buy |
73,267
+52,775
| +258% | +$1.87M | ﹤0.01% | 1948 |
|
|
2024
Q4 | $741K | Sell |
20,492
-475
| -2% | -$16.7K | ﹤0.01% | 3350 |
|
|
2024
Q3 | $654K | Buy |
+20,967
| New | +$654K | ﹤0.01% | 2920 |
|
|
2023
Q4 | – | Sell |
-14,551
| Closed | -$401K | – | 4488 |
|
|
2023
Q3 | $401K | Sell |
14,551
-1,104
| -7% | -$33.6K | ﹤0.01% | 2949 |
|
|
2023
Q2 | $471K | Buy |
15,655
+3,199
| +26% | +$112K | ﹤0.01% | 2653 |
|
|
2023
Q1 | $451K | Sell |
12,456
-19,888
| -61% | -$765K | ﹤0.01% | 2361 |
|
|
2022
Q4 | $1.15M | Sell |
32,344
-8,498
| -21% | -$295K | ﹤0.01% | 1728 |
|
|
2022
Q3 | $1.38M | Buy |
+40,842
| New | +$1.33M | 0.01% | 1553 |
|
|
2022
Q2 | – | Sell |
-13,785
| Closed | -$446K | – | 3362 |
|
|
2022
Q1 | $446K | Sell |
13,785
-20,307
| -60% | -$623K | ﹤0.01% | 2071 |
|
|
2021
Q4 | $994K | Buy |
+34,092
| New | +$1.03M | ﹤0.01% | 1700 |
|
|
2021
Q2 | – | Sell |
-22,764
| Closed | -$596K | – | 3676 |
|
|
2021
Q1 | $596K | Buy |
22,764
+8,709
| +62% | +$244K | ﹤0.01% | 1890 |
|
|
2020
Q4 | $354K | Sell |
14,055
-23,132
| -62% | -$498K | ﹤0.01% | 2084 |
|
|
2020
Q3 | $775K | Sell |
37,187
-24,544
| -40% | -$557K | 0.01% | 1137 |
|
|
2020
Q2 | $1.47M | Buy |
61,731
+1,623
| +3% | +$35.9K | 0.02% | 758 |
|
|
2020
Q1 | $1.08M | Sell |
60,108
-28,923
| -32% | -$608K | 0.03% | 690 |
|
|
2019
Q4 | $2.11M | Buy |
89,031
+39,579
| +80% | +$961K | 0.01% | 875 |
|
|
2019
Q3 | $1.36M | Buy |
49,452
+37,928
| +329% | +$1.12M | 0.01% | 1024 |
|
|
2019
Q2 | $381K | Sell |
11,524
-50,621
| -81% | -$1.73M | ﹤0.01% | 1819 |
|
|
2019
Q1 | $2.18M | Buy |
62,145
+43,843
| +240% | +$1.63M | 0.02% | 740 |
|
|
2018
Q4 | $608K | Buy |
18,302
+866
| +5% | +$37.2K | 0.01% | 1153 |
|
|
2018
Q3 | $878K | Buy |
+17,436
| New | +$861K | 0.01% | 1053 |
|
|
2018
Q2 | – | Sell |
-56,569
| Closed | -$2.59M | – | 2037 |
|
|
2018
Q1 | $2.59M | Buy |
56,569
+47,122
| +499% | +$1.97M | 0.04% | 487 |
|
|
2017
Q4 | $376K | Sell |
9,447
-42,729
| -82% | -$1.69M | 0.01% | 1363 |
|
|
2017
Q3 | $2.09M | Buy |
52,176
+5,869
| +13% | +$254K | 0.04% | 492 |
|
|
2017
Q2 | $2M | Buy |
46,307
+3,156
| +7% | +$112K | 0.04% | 518 |
|
|
2017
Q1 | $1.35M | Buy |
43,151
+10,065
| +30% | +$270K | 0.04% | 500 |
|
|
2016
Q4 | $835K | Buy |
+33,086
| New | +$739K | 0.03% | 577 |
|
|
2016
Q3 | – | Sell |
-11,861
| Closed | -$242K | – | 1246 |
|
|
2016
Q2 | $242K | Sell |
11,861
-13,133
| -53% | -$233K | 0.02% | 824 |
|
|
2016
Q1 | $381K | Sell |
24,994
-3,500
| -12% | -$45.7K | 0.03% | 731 |
|
|
2015
Q4 | $383K | Buy |
+28,494
| New | +$441K | 0.04% | 678 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Squarepoint's SUPN Position: Q1 2026 in Review
Squarepoint reduced its Supernus Pharmaceuticals (SUPN) stake by 72% in Q1 2026, selling an estimated $3.41M and leaving 25,524 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2534.
Squarepoint first reported a position in SUPN in Q4 2015 and has held it in 34 quarters since. The position peaked at $4.59M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Squarepoint held 25,524 shares of Supernus Pharmaceuticals worth $1.32M as of Q1 2026.
- Squarepoint sold 66,923 Supernus Pharmaceuticals shares in Q1 2026, an estimated $3.41M.
- Supernus Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2534 holding.
- Squarepoint first reported a position in Supernus Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
- Squarepoint's Supernus Pharmaceuticals position peaked at $4.59M in Q4 2025.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.